On Wednesday, Encana Corporation (NYSE:ECA)’s shares surged 6.71% to $12.72, as oil prices continued to rise for a second day on lower-than-predictable U.S. oil inventory levels.
WTI crude oil for May delivery was up 4.5% to $55.69 a barrel early Wednesday afternoon, and Brent crude oil for May delivery was up 2.6% to $59.93 a barrel.
Encana Corporation, together with its auxiliaries, engages in the development, exploration, production, and marketing of natural gas, oil, and natural gas liquids in Canada and the United States.
Horizon Pharma plc (NASDAQ:HZNP)’s shares gained 6.69% to $29.50, during the last trading session on Wednesday, hitting its highest level.
Horizon Pharma, declared the pricing of its underwritten public offering of 15,350,000 of its ordinary shares at a price to the public of $28.25 per share. The net proceeds to Horizon from this offering are predictable to be about $413.1 million, after deducting underwriting discounts and other offering expenses payable by Horizon. Horizon has also granted the underwriters a 30-day option to purchase up to an additional 2,302,500 ordinary shares. The offering is predictable to close on or about April 21, 2015, subject to customary closing conditions.
Citigroup, Jefferies LLC, Cowen and Company, LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for this offering.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
At the end of Wednesday’s trade, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s shares gained 6.59% to $0.97.
Lexicon Pharmaceuticals, declared that the company and Bristol-Myers Squibb have selected a development candidate for neuropathic pain as part of their neuroscience drug discovery and development alliance. Lexicon and Bristol-Myers Squibb are proceeding with plans to progress the development candidate through IND-enabling studies in preparation for the commencement of clinical trials. Bristol-Myers Squibb has the first option under the alliance to obtain exclusive clinical development and commercialization rights upon the initiation of Phase 1 clinical studies, subject to the payment of milestones and royalties to Lexicon.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs comprise telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
Finally, Atwood Oceanics, Inc. (NYSE:ATW), ended its Wednesday’s trading session with 6.59% gain, and closed at $33.32.
Atwood Oceanics, declared that it would declare Second Quarter 2015 Earnings after the market closes on Wednesday, April 29, 2015. The company will hold its conference call and webcast in conjunction with its Fiscal 2015 Second Quarter Earnings Release on Thursday April 30, 2015 at 9:00 A.M. CDT (10:00 A.M. EDT).
The company`s conference call that will be broadcast live over the Internet at 9:00 A.M. CDT, Thursday April 30, 2015 with Rob Saltiel, President and CEO, and Mark Mey, Executive Vice President and CFO, participating.
Atwood Oceanics, Inc., an offshore drilling contractor, engages in the drilling and completion of exploratory and developmental oil and gas wells worldwide. As of November 10, 2014, it owned a fleet of 13 mobile offshore drilling units, in addition to 3 ultra-deepwater drill ships under construction. The company was founded in 1968 and is headquartered in Houston, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
